OpGen

OpGen P/TBV

The Price to Tangible Book Value (P/TBV) of OpGen (OPGN) as of Nov 10, 2026 is 11.46. In the previous year, Price to Tangible Book Value (P/TBV) was 49.48 — a change of -76.83% (lower).

P/TBV

11.46

YoY

-76.83%

Last updated:

Price to Tangible Book Value (P/TBV) of OpGen is 2025 11.46 . Price to Tangible Book Value (P/TBV) of OpGen was 2024 49.48 . It decreases by -76.83% lower compared to the previous year.

The OpGen P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
225.04 USD
Jan 1, 2019
127.06 USD
Jan 1, 2020
-106.96 USD
Jan 1, 2021
18.99 USD
Jan 1, 2022
2,706.48 USD
Jan 1, 2023
-31.59 USD
Jan 1, 2024
49.48 USD
Jan 1, 2025
11.46 USD
The OpGen P/TBV history
YEARP/TBVYoY
11.46-76.83%
49.48-256.65%
-31.59-101.17%
2,706.48+14,153.27%
18.99-117.75%
-106.96-184.19%
127.06-43.54%
225.04-134.06%
-660.66-271.06%
386.21+424.98%
73.57-262.47%
-45.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Price to Tangible Book Value (P/TBV) of OpGen is 11.46 in 2025.

Price to Tangible Book Value (P/TBV) of OpGen changed from 49.48 to 11.46, representing a -76.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) OpGen since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OpGen

All Key Metrics — OpGen